argenex SE $ARGX Shares Sold by Aberdeen Group plc

Aberdeen Group plc lowered its stake in shares of argenex SE (NASDAQ:ARGX) by 21.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 52,347 shares of the company’s stock after selling 14,329 shares during the period. Aberdeen Group plc owned approximately 0.09% of argenex worth $44,021,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ARGX. Wellington Management Group LLP boosted its position in shares of argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the period. Two Sigma Investments LP increased its stake in argenex by 570.3% during the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of argenex by 114.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock worth $163,775,000 after purchasing an additional 158,476 shares in the last quarter. Woodline Partners LP boosted its stake in shares of argenex by 320.8% in the third quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock valued at $124,999,000 after purchasing an additional 129,205 shares during the period. Finally, Alkeon Capital Management LLC boosted its stake in shares of argenex by 133.3% in the third quarter. Alkeon Capital Management LLC now owns 175,000 shares of the company’s stock valued at $129,073,000 after purchasing an additional 100,000 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the topic of a number of research reports. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Royal Bank Of Canada cut their price objective on argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Wedbush reiterated an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research note on Monday, March 9th. Wells Fargo & Company decreased their target price on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Finally, JPMorgan Chase & Co. boosted their target price on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $1,016.22.

argenex Price Performance

Shares of NASDAQ ARGX opened at $746.42 on Friday. The company has a market capitalization of $46.19 billion, a price-to-earnings ratio of 38.24, a price-to-earnings-growth ratio of 1.23 and a beta of 0.46. The business has a 50-day moving average of $773.10 and a two-hundred day moving average of $813.07. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Saturday, February 14th. The company reported $8.02 EPS for the quarter. argenex had a return on equity of 38.51% and a net margin of 30.42%. As a group, equities research analysts expect that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.